JPMorgan analyst Brian Cheng raised the firm’s price target on Roivant Sciences to $16 from $14 and keeps an Overweight rating on the shares following a model update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- Roivant Stock (NASDAQ:ROIV) Soars on $7B Potential Sale of Colitis Drug
- Roivant Sciences jumps 15% to $13.30 after WSJ report on potential RVT-3101 sale
- Roivant Sciences near deal to sell stomach drug to Roche for over $7B, WSJ says
- Roivant rises after Bloomberg says IBD drug attracting big pharma interest
- Roivant Sciences trading resumes